Hong Kong Banks Stock News

Hansoh Pharmaceutical Group (SEHK:3692) has drawn fresh investor attention after announcing that its self developed Class 1 drug candidate HS-10541 received clinical trial approval in China for KRAS G12C mutated advanced solid tumors. See our latest analysis for Hansoh Pharmaceutical Group. The HS-10541 trial approval comes as Hansoh Pharmaceutical Group's share price has softened recently, with a 30 day share price return down 13.62%, even while the 1 year total shareholder return stands at...

The recent 10% drop in Eagle Nice (International) Holdings Limited's ( HKG:2368 ) stock could come as a blow to...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

As the Asian markets navigate a complex landscape of geopolitical tensions and economic uncertainties, investors are increasingly focused on companies with strong growth potential and significant insider ownership. In this environment, stocks that combine robust internal backing with promising expansion prospects can offer a compelling investment narrative.

As global markets navigate a complex landscape marked by inflation concerns and geopolitical tensions, the Asian market remains a focal point for investors seeking opportunities in emerging sectors. Penny stocks, though an older term, continue to represent smaller or less-established companies that can offer significant value and growth potential. By focusing on those with robust financials and clear growth trajectories, investors might uncover promising opportunities among these lesser-known...

Electric vehicle demand and technical rebound thesis Recent analyst commentary on Aluminum Corporation of China (SEHK:2600) discusses a potential technical rebound, connecting current interest in the stock to aluminum demand associated with the expanding electric vehicle industry. See our latest analysis for Aluminum Corporation of China. At the latest share price of HK$11.88, the stock has seen a sharp 1-day share price return of 9.29% and 7-day share price return of 14.56%, even though the...

Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after winning a positive opinion from the EMA’s CHMP for serplulimab plus chemotherapy in first-line advanced squamous non-small cell lung cancer in Europe. See our latest analysis for Shanghai Henlius Biotech. Despite the positive CHMP opinion and a series of product updates, Shanghai Henlius Biotech’s short term share price return has come under pressure, with the 1 month share price return down 17.22%. However, the 1 year...

Amidst a backdrop of rising inflation worries and fluctuating consumer sentiment, global markets have shown resilience, with major U.S. stock indexes reaching new highs and small-cap stocks outperforming their larger peers. In such a dynamic market landscape, investors often look beyond the well-trodden paths to discover potential in lesser-known areas like penny stocks. While the term "penny stocks" might seem outdated, these smaller or newer companies can offer unique growth opportunities...

BrainAurora Medical Technology Limited's (HKG:6681) stock price has dropped 28% in the previous week, but insiders who...

Earnings and gaming deal put Tencent in focus Tencent Holdings (SEHK:700) has drawn fresh attention after reporting first quarter 2026 results, alongside a ten year renewal of its Dungeon&Fighter publishing partnership with NEXON in China, a combination that keeps its gaming business in clear view for investors. See our latest analysis for Tencent Holdings. Despite the Q1 earnings update and the renewed Dungeon&Fighter deal, Tencent’s share price has been under pressure, with the stock down...

Alphamab Oncology (SEHK:9966) has dosed the first patient in its phase II trial of JSKN033, a high concentration subcutaneous HER2 bispecific ADC and PD-L1 therapy combined with platinum-based chemotherapy for advanced cervical cancer. See our latest analysis for Alphamab Oncology. The JSKN033 update comes as momentum around Alphamab Oncology's HK$9.35 share price has picked up in the very near term, with a 1-day share price return of 6.25% and 7-day share price return of 10.91%, following a...

CSPC Pharmaceutical Group (SEHK:1093) has recently secured Chinese approvals for Enyike, a ustekinumab biosimilar, and 4mg budesonide enteric-coated capsules, broadening its autoimmune and nephrology treatment offerings for patients. See our latest analysis for CSPC Pharmaceutical Group. At a latest share price of HK$7.69, the stock has seen a 1-day share price return of 4.77% and a 7-day share price return of 1.45%, but a 90-day share price return that is down 23.56%. The 1-year total...

Investors who take an interest in China Qinfa Group Limited ( HKG:866 ) should definitely note that the CEO, President...

From what we can see, insiders were net sellers in CHYY Development Group Limited's ( HKG:8128 ) during the past 12...

Potential Gudou Holdings Limited ( HKG:8308 ) shareholders may wish to note that the CEO & Executive Director, Guowei...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Insiders who bought Wai Chun Bio-Technology Limited ( HKG:660 ) stock lover the last 12 months are probably not as...

Recent governance changes at Haitian International Holdings (SEHK:1882), including the appointment of Xiang Linfa as Executive Director, refreshed board compositions, and strong AGM support for capital mandates, have put the stock’s leadership and oversight structure in focus. See our latest analysis for Haitian International Holdings. At a latest share price of HK$20.88, Haitian International’s recent governance updates come against a mixed backdrop, with the 1-day share price return up...

Nexteer Automotive Group (SEHK:1316) is back on investor radars after Guoyuan International highlighted its steer-by-wire rollout and sizeable Q1 2026 order wins, along with a higher full-year order target. See our latest analysis for Nexteer Automotive Group. The recent steer-by-wire progress and Q1 2026 order intake have coincided with short term share price momentum, with a 1-month share price return of 3.16% and a 1-year total shareholder return that is still down 17.33%, suggesting...

HBM Holdings (SEHK:2142) is in focus after Harbour BioMed reported preclinical data for LET003, an ACVR2A/2B-targeting antibody developed using its AI-based Hu-mAtrIx platform, showing superior pharmacokinetics compared with several competitors. See our latest analysis for HBM Holdings. At a share price of HK$12.15, HBM Holdings has seen the 30 day share price return fall 13.21%, even as the 1 year total shareholder return is 37.91% and the 3 year total shareholder return is very large. This...

Why the latest operating data matters for investors China Resources Power Holdings (SEHK:836) has reported new operating figures for April and the first four months of 2026, with higher total net generation supported by strong photovoltaic output, which offset weaker wind generation. See our latest analysis for China Resources Power Holdings. At a share price of HK$20.18, the stock has built clear positive momentum, with a 90-day share price return of 10.27% and a 5-year total shareholder...

Amid a backdrop of rising inflation concerns and geopolitical tensions, major U.S. stock indexes have reached new heights, driven by enthusiasm around artificial intelligence stocks and positive earnings reports. As the market landscape continues to evolve, investors might find opportunities in areas often overlooked by mainstream attention. Penny stocks, though sometimes seen as relics of past speculative trends, remain relevant for those seeking growth potential in smaller or newer...

SINOPEC Engineering (Group) (SEHK:2386) is in focus after Chairman and executive director Mr. JIANG Dejun resigned, stepping down from several key board committees. The company cited age and noted there were no disagreements. See our latest analysis for SINOPEC Engineering (Group). The share price has fallen around 25% over the past three months and is down about 25% year to date, even though the 3 year total shareholder return is about 101%. This means recent momentum appears weaker than the...

BYD (SEHK:1211) is back in focus after Chinese automakers more than doubled European electric vehicle sales in April, reaching 38,281 units and surpassing 15% of the region's EV market. See our latest analysis for BYD. Despite the strong headlines around European EV expansion and battery range gains, BYD's recent share price performance has been soft, with the 30 day share price return down 9.49% and the 1 year total shareholder return down 40.28%, even though the 5 year total shareholder...